CAMP4
PublicCAMP4 is now publicly traded
The data on this page reflects CAMP4's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Follow-on Offering
Dec 18, 2025
Est. Valuation at Exit
$311.28M
Total Funding Raised
$255M
Company Overview
CAMP4 is a biopharmaceutical company specializing in the discovery and development of regulatory RNA-based therapeutics aimed at enhancing gene expression and restoring healthy protein levels to address genetic diseases, particularly those affecting the central nervous system and liver.
Sector
Biotech
AI Layer
Non-AI
Keywords
CAMP4 Comparables
Compare CAMP4 with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MiNA Therapeutics | 82% | |
| Creyon Bio | 73% | |
| Harness Therapeutics | 73% |
CAMP4 Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Dec 18, 2025 | ||||
| Private Placement | Sep 10, 2025 | ||||
| Series B | Jul 20, 2022 | ||||
| Series A Extension | Jun 15, 2021 | ||||
| Series A | Apr 20, 2018 |
CAMP4 Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Follow-on Offering |
| Andreessen Horowitz | Series A Extension, Series B, Series A |
| Enavate Sciences | Series B |
| Janus Henderson Group | Private Placement, Follow-on Offering |
| Balyasny Asset Management L.P. | Private Placement |
| Gaingels | Series B |
| Patient Square Capital | Series B |
CAMP4 Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access